Omeprazolo Fg (Omeprazole)

Omeprazole, the active ingredient in Omeprazolo Fg, is a Proton Pump Inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to manage gastro‑reflux related conditions in adults and children. GNH USA supplies Omeprazolo Fg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazolo Fg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): alleviates heartburn and promotes healing of erosive esophagitis. - Peptic ulcer disease (PUD): supports ulcer healing and reduces risk of recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - NSAID‑associated ulcer prevention: lowers risk of ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally dose‑dependent and may vary in frequency.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or vomiting: transient gastrointestinal upset. - Abdominal pain or flatulence: mild discomfort. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis risk. - Acute interstitial nephritis: renal inflammation. - Hypomagnesemia: low serum magnesium levels. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions. - Liver enzyme elevation: potential hepatotoxicity. - Fracture risk: possible reduction in bone mineral density with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal and hepatic function: dose adjustment may be required in impairment. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term users: evaluate need for continued therapy after 8‑12 weeks. - Pregnancy and lactation: use only if clearly indicated after risk‑benefit assessment. - Elderly patients: start with the lowest effective dose and monitor for adverse effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir or other protease inhibitors: decreased absorption, loss of antiviral efficacy. - Warfarin: enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely): - Methotrexate: increased serum levels, risk of toxicity. - Digoxin: higher plasma concentrations, monitor cardiac status. - Diazepam: elevated levels may cause sedation, adjust dose if needed. - Iron supplements: reduced absorption, separate dosing by at least 2 hours.